RMD ResMed Inc.

ResMed Announces SaaS Leadership Change

ResMed Announces SaaS Leadership Change

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed’s SaaS business

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business, effective immediately. Raj Sodhi will be leaving full-time employment at ResMed, effective September 1.

Bobby has over 25 years of experience across medical and technology industries, most currently serving as ResMed’s Chief Technology Officer (CTO), with strong experience building and leading high-performing teams to accelerate the adoption of digital platforms across enterprises. From February 2016 until April 2018, Bobby served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care. ResMed will commence a search process for a new CTO immediately; Bobby will remain in the CTO role until a replacement is found.

“As we look ahead to 2025, we believe the future of healthcare is outside the hospital and we have an amazing mission to improve over 250 million lives,” said Mick Farrell, ResMed’s CEO. “We must accelerate our efforts to bring software technology, along with digital and commercial innovation, to these care settings. Digital solutions, scalable digital platforms, and software embedded into our customers’ workflows are critical to our growth strategy – Bobby’s experience as ResMed’s CTO, his hands-on experience with Brightree, and his strong background across many industries makes him the right leader to accelerate our SaaS business to meet our goals for 2025 and beyond.”

“I’d like to thank Raj for the incredible work he’s done over the past nine years at ResMed,” continued Farrell. “Raj played an important role in developing the healthcare informatics function at ResMed, a function that helped to transform the company on our path to becoming the leader in digital health. He also helped to craft the SaaS strategy and lead multiple acquisitions that established the foundation for us to scale and grow our SaaS business in home medical equipment, skilled nursing facilities, home health, hospice, private duty homecare, and beyond.”

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investorsFor media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 858.836.6798



EN
25/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors...

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company als...

 PRESS RELEASE

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue incre...

 PRESS RELEASE

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / ...

ResMed Inc: 1 director

A director at ResMed Inc sold 2,000 shares at 247.320USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Resmed Champions Sleep Health as The Official Sleep Partner of The Qat...

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans’ dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will b...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch